LPAA

Launch One Acquisition Corp

Apr 08 • 04:00PM ET

10.88

+0.15 1.40 %

Financial • Shell Companies • USA • NASD

Index	-	P/E	37.65	EPS (ttm)	0.29	Insider Own	20.00%	Shs Outstand	23.00M	Perf Week	1.59%
Market Cap	310.21M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	23.00M	Perf Month	1.97%
Enterprise Value	310.18M	PEG	-	EPS next Q	-	Inst Own	79.47%	Short Float	0.01%	Perf Quarter	2.64%
Income	8.31M	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.23	Perf Half Y	3.52%
Sales	0.00M	P/B	1.34	EPS next Y	-	ROA	3.45%	Short Interest	0.00M	Perf YTD	2.74%
Book/sh	8.14	P/C	10340.33	EPS next 5Y	-	ROE	3.62%	52W High	10.74 1.30%	Perf Year	6.56%
Cash/sh	0.00	P/FCF	-	EPS past 3/5Y	- -	ROIC	3.55%	52W Low	10.21 6.56%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	0.02% 0.08%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	61.54%	Oper. Margin	-	ATR (14)	0.03	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.23	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	75.87	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	0.23	EPS Q/Q	-18.50%	SMA20	1.70%	Beta	0.02	Target Price	-
Payout	0.00%	Debt/Eq	0.00	Sales Q/Q	-	SMA50	2.11%	Rel Volume	0.00	Prev Close	10.73
Employees	2	LT Debt/Eq	0.00	Earnings	-	SMA200	3.50%	Avg Volume	7.80K	Price	10.88
IPO	Sep 03, 2024	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	1	Change	1.40%

Jan-13-26 10:15AM	Minovia Therapeutics Announces Two New U.S. Patents Granted, Strengthening Its Mitochondrial Augmentation Therapy Platform (GlobeNewswire)
Nov-20-25 08:30AM	Minovia Therapeutics Mitochondrial Augmentation Technology to be Featured in Presentation and Workshop at the 67th ASH Annual Meeting and Exposition (GlobeNewswire)
Oct-15-25 07:30AM	Minovia Therapeutics Receives FDA Orphan Drug Designation for MNV-201 in Myelodysplastic Syndrome (GlobeNewswire)
Sep-18-25 07:30AM	Minovia Therapeutics Receives FDA Fast Track Designation for MNV-201 in Myelodysplastic Syndrome (GlobeNewswire)
Aug-27-25 07:15AM	Minovia Therapeutics Announces $350,000 Grant from Countdown for a Cure Foundation to Develop Mitochondria Blood-Based Biomarkers (GlobeNewswire)
08:15AM	Loading…
Jul-24-25 08:15AM	Minovia Therapeutics Announces Interim Data from Phase 2 Trial in Pearson Syndrome Demonstrating No Treatment-Related Serious Adverse Events and Preliminary Signal for Efficacy Measured by Growth (GlobeNewswire)
Jun-30-25 08:30AM	Minovia Therapeutics Announces FDA Fast Track and Rare Pediatric Disease Designations for MNV-201 in Pearson Syndrome (GlobeNewswire)
Jun-25-25 08:30AM	Minovia Therapeutics Ltd. and Launch One Acquisition Corp. Announce Proposed Business Combination to Create Nasdaq-Listed Mitochondrial Therapy Company in $1 Trillion+ Mitochondrial and Longevity Markets (GlobeNewswire)

Launch One Acquisition Corp. is a blank check company, which engages for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on February 21, 2024 and is headquartered in Oakland, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LPAA

Launch One Acquisition Corp

Upgrade your Finviz experience